Brian S. Kim

From Wikitia
Jump to navigation Jump to search
Brian S. Kim, MD MTR
Add a Photo
Education
  • Haverford College
  • Washington University School of Medicine
  • University of Pennsylvania School of Medicine
Occupation
  • Sol and Clara Kest Professor
  • Vice Chair of Research
  • Site Chair
  • Director of Mark Lebwohl Center
Medical career
Field
  • Dermatology
  • Allergy
  • Immunology
InstitutionsMount Sinai Health System
WebsiteKim Lab

Brian S. Kim is the Sol wand Clara Kest Professor, Vice Chair of Research, and Site Chair of Mount Sinai West and Morningside in the Kimberly and Eric J. Waldman Department of Dermatology at Icahn School of Medicine at Mount Sinai[1][2][3]. He is also Director of the Mark Lebwohl Center for Neuroinflammation and Sensation[4].

Education

Dr. Kim received his B.S. in chemistry with honors from Haverford College in 2001 and his M.D. from the University of Washington in 2007. He was a Howard Hughes Medical Institute-National Institutes of Health Research Scholar under Dr. Stephen I. Katz, and completed his residency in dermatology at the Perelman School of Medicine at the University of Pennsylvania[5][6]. He completed a postdoctoral fellowship under Dr. David Artis[7], leading to a Master of Translational Research.

Research

Dr. Kim’s laboratory.[8] focuses on the regulatory mechanisms that underlie skin inflammation and the sensation of itch as a model paradigm of neuroimmunology. Key discoveries include the first identification of group 2 innate lymphoid cells (ILC2s)[9] in the skin of both mice and humans, novel contributions of basophils[10], ILC2s[11], and natural killer (NK) cells to skin inflammation[12], and unveiling how different innate immune cells and type 2 cytokines/JAK signaling directly influence sensory neuronal responses[13].

His was was first to identify IL-4 receptor signaling on sensory neurons[14], which critically informed new therapies like dupilumab[15]. Dr. Kim's group also was the first lab to identify JAK1 signaling in sensory neurons[16], building on previous research which showed a significant reduction of itch symptoms in response to treatment with JAK inhibitors[17][18]. While these previous works investigated JAK inhibition as an anti-inflammatory treatment, Dr. Kim and colleagues found that disruption of neuronal JAK1 signaling limits both inflammatory and non-inflammatory itch, suggesting that JAK inhibitors may represent a novel neuromodulatory approach to target itch in atopic dermatitis[19]

His research in neuroimmune regulation of itch and atopic dermatitis has led to awards and funding from the NIH, Doris Duke Charitable Foundation[20], American Skin Association[21], American Academy of Dermatology (2014 Young Investigator Award[22]), American Society for Clinical Investigation[23], American Dermatological Association, and International League of Dermatological Societies. He holds a patent for the use of JAK inhibitors for chronic itch.US patent WO2017143014A1  He is on the scientific advisory board for Abrax Japan,[24] Granular Therapeutics,[25] Recens Medical, National Eczema Association,[26] and Cell Reports Medicine[27]. He is section editor for Journal of Immunology[28] and on the board of reviewing editors for eLife[29] and Journal of Allergy and Clinical Immunology.

References

  1. ↑ "Brian S. Kim - Dermatology | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2022-08-29.
  2. ↑ "Brian S. Kim". Brian Kim Lab. Retrieved 2022-08-29.
  3. ↑ "Brian S. Kim | Icahn School of Medicine". Icahn School of Medicine at Mount Sinai. Retrieved 2022-08-29.
  4. ↑ "Top Researcher of Itch and Inflammatory Skin Conditions to Join Mount Sinai's Department of Dermatology | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2022-08-29.
  5. ↑ "Dr. Brian Kim, MD – New York, NY | Dermatology on Doximity". Doximity. Retrieved 2022-08-29.
  6. ↑ "ORCID". orcid.org. Retrieved 2022-08-29.
  7. ↑ "T32 Past Trainees". Penn Dermatology Training. Retrieved 2022-08-29.
  8. ↑ Kim, Brian. "Kim Lab".
  9. ↑ Kim, Brian S; Artis, David (May 7, 2015). "Group 2 Innate Lymphoid Cells in Health and Disease". Cold Spring Harb Perspect Biol.
  10. ↑ Wang, F; Trier, AM; Li, F; Kim, S; Chen, Z; Chai, JN; Mack, MR; Morrison, SA; Hamilton, JD; Baek, J; Yang, TB; Ver Heul, AM; Xu, AZ; Xie, Z; Dong, X; Kubo, M; Hu, H; Hsieh, CS; Dong, X; Liu, Q; Margolis, DJ; Ardeleanu, M; Miller, MJ; Kim, BS (21 January 2021). "A basophil-neuronal axis promotes itch". Cell. 184 (2): 422-440.e17. doi:10.1016/j.cell.2020.12.033. PMID 33450207.
  11. ↑ Kim, BS; Wang, K; Siracusa, MC; Saenz, SA; Brestoff, JR; Monticelli, LA; Noti, M; Tait Wojno, ED; Fung, TC; Kubo, M; Artis, D (1 October 2014). "Basophils promote innate lymphoid cell responses in inflamed skin". Journal of immunology (Baltimore, Md. : 1950). 193 (7): 3717–25. doi:10.4049/jimmunol.1401307. PMID 25156365.
  12. ↑ Mack, MR; Brestoff, JR; Berrien-Elliott, MM; Trier, AM; Yang, TB; McCullen, M; Collins, PL; Niu, H; Bodet, ND; Wagner, JA; Park, E; Xu, AZ; Wang, F; Chibnall, R; Council, ML; Heffington, C; Kreisel, F; Margolis, DJ; Sheinbein, D; Lovato, P; Vivier, E; Cella, M; Colonna, M; Yokoyama, WM; Oltz, EM; Fehniger, TA; Kim, BS (26 February 2020). "Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis". Science translational medicine. 12 (532). doi:10.1126/scitranslmed.aay1005. PMID 32102931.
  13. ↑ Oetjen, LK; Mack, MR; Feng, J; Whelan, TM; Niu, H; Guo, CJ; Chen, S; Trier, AM; Xu, AZ; Tripathi, SV; Luo, J; Gao, X; Yang, L; Hamilton, SL; Wang, PL; Brestoff, JR; Council, ML; Brasington, R; Schaffer, A; Brombacher, F; Hsieh, CS; Gereau RW, 4th; Miller, MJ; Chen, ZF; Hu, H; Davidson, S; Liu, Q; Kim, BS (21 September 2017). "Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch". Cell. 171 (1): 217-228.e13. doi:10.1016/j.cell.2017.08.006. PMID 28890086.
  14. ↑ Oetjen, LK; Mack, MR; Feng, J; Whelan, TM; Niu, H; Guo, CJ; Chen, S; Trier, AM; Xu, AZ; Tripathi, SV; Luo, J; Gao, X; Yang, L; Hamilton, SL; Wang, PL; Brestoff, JR; Council, ML; Brasington, R; Schaffer, A; Brombacher, F; Hsieh, CS; Gereau RW, 4th; Miller, MJ; Chen, ZF; Hu, H; Davidson, S; Liu, Q; Kim, BS (21 September 2017). "Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch". Cell. 171 (1): 217-228.e13. doi:10.1016/j.cell.2017.08.006. PMID 28890086.
  15. ↑ Guttman-Yassky, E; Bissonnette, R; Ungar, B; Suárez-Fariñas, M; Ardeleanu, M; Esaki, H; Suprun, M; Estrada, Y; Xu, H; Peng, X; Silverberg, JI; Menter, A; Krueger, JG; Zhang, R; Chaudhry, U; Swanson, B; Graham, NMH; Pirozzi, G; Yancopoulos, GD; D Hamilton, JD (January 2019). "Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis". The Journal of allergy and clinical immunology. 143 (1): 155–172. doi:10.1016/j.jaci.2018.08.022. PMID 30194992.
  16. ↑ Oetjen, LK; Mack, MR; Feng, J; Whelan, TM; Niu, H; Guo, CJ; Chen, S; Trier, AM; Xu, AZ; Tripathi, SV; Luo, J; Gao, X; Yang, L; Hamilton, SL; Wang, PL; Brestoff, JR; Council, ML; Brasington, R; Schaffer, A; Brombacher, F; Hsieh, CS; Gereau RW, 4th; Miller, MJ; Chen, ZF; Hu, H; Davidson, S; Liu, Q; Kim, BS (21 September 2017). "Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch". Cell. 171 (1): 217-228.e13. doi:10.1016/j.cell.2017.08.006. PMID 28890086.
  17. ↑ Levy, LL; Urban, J; King, BA (September 2015). "Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate". Journal of the American Academy of Dermatology. 73 (3): 395–9. doi:10.1016/j.jaad.2015.06.045. PMID 26194706.
  18. ↑ Bissonnette, R; Papp, KA; Poulin, Y; Gooderham, M; Raman, M; Mallbris, L; Wang, C; Purohit, V; Mamolo, C; Papacharalambous, J; Ports, WC (November 2016). "Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial". The British journal of dermatology. 175 (5): 902–911. doi:10.1111/bjd.14871. PMID 27423107.
  19. ↑ Oetjen, LK; Mack, MR; Feng, J; Whelan, TM; Niu, H; Guo, CJ; Chen, S; Trier, AM; Xu, AZ; Tripathi, SV; Luo, J; Gao, X; Yang, L; Hamilton, SL; Wang, PL; Brestoff, JR; Council, ML; Brasington, R; Schaffer, A; Brombacher, F; Hsieh, CS; Gereau RW, 4th; Miller, MJ; Chen, ZF; Hu, H; Davidson, S; Liu, Q; Kim, BS (21 September 2017). "Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch". Cell. 171 (1): 217-228.e13. doi:10.1016/j.cell.2017.08.006. PMID 28890086.
  20. ↑ "Home - Doris Duke Charitable Foundation". www.ddcf.org.
  21. ↑ "Dr. Brian Kim receives American Skin Association's 2021 Research Achievement Award in Discovery". Division of Dermatology. Washington University School of Medicine in St. Louis. 10 May 2021.
  22. ↑ "Young Investigator Awards". www.aad.org.
  23. ↑ "The American Society for Clinical Investigation".
  24. ↑ "Board of Directors at Abrax - Abrax Japan - English Site". en.abrax-japan.com. 14 August 2021. Retrieved 16 May 2022.
  25. ↑ "Home". Granular Therapeutics. Retrieved 16 May 2022.
  26. ↑ "Scientific and Medical Advisory Council". National Eczema Association. Retrieved 16 May 2022.
  27. ↑ "Advisory board: Cell Reports Medicine". www.cell.com. Retrieved 16 May 2022.
  28. ↑ "Editorial Board The Journal of Immunology". www.jimmunol.org. Retrieved 16 May 2022.
  29. ↑ "Editors for Immunology and Inflammation". eLife. Retrieved 16 May 2022.

External links

Add External links

This article "Brian S. Kim" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.

Retrieved from "https://wikitia.com/index.php?title=Brian_S._Kim&oldid=162861"